Trials / Completed
CompletedNCT04551963
Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
A Drug-Drug Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Patients With B-Cell Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study was to assess the steady-state zanubrutinib pharmacokinetics (PK) when co-administered with moderate and strong cytochrome P450 family 3 subfamily A (CYP3A) inhibitors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zanubrutinib | Capsules administered at a dose and frequency as specified in the treatment arm |
| DRUG | Fluconazole | Capsules administered at a dose and frequency as specified in the treatment arm |
| DRUG | Diltiazem | Capsules administered at a dose and frequency as specified in the treatment arm |
| DRUG | Voriconazole | Capsules administered at a dose and frequency as specified in the treatment arm |
| DRUG | Clarithromycin | Capsules administered at a dose and frequency as specified in the treatment arm |
Timeline
- Start date
- 2020-11-15
- Primary completion
- 2022-02-21
- Completion
- 2022-02-21
- First posted
- 2020-09-16
- Last updated
- 2024-10-26
- Results posted
- 2023-11-27
Locations
7 sites across 1 country: Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04551963. Inclusion in this directory is not an endorsement.